Immunotherapy for Alzheimer’s Disease: Past, Present and Future
Alzheimer’s disease (AD) is an incurable, progressive, neurodegenerative disorder affecting over 5 million people in the US alone. This neurological disorder is characterized by widespread neurodegeneration throughout the association cortex and limbic system caused by deposition of Aβ resulting in t...
Main Authors: | Brian eSpencer, Eliezer eMasliah |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-06-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00114/full |
Similar Items
-
A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease
by: Gerhard Leinenga, et al.
Published: (2021-04-01) -
Tau oligomers: the toxic player at synapses in Alzheimer’s disease
by: Marcos Jair Guerrero-Munoz, et al.
Published: (2015-12-01) -
Etude préclinique et clinique de la phase précoce de la maladie d'Alzheimer
by: Epelbaum, Stéphane
Published: (2015) -
Chemokines in Alzheimer’s Disease: New Insights Into Prokineticins, Chemokine-Like Proteins
by: Anna Rita Zuena, et al.
Published: (2019-05-01) -
Immunotherapy for Alzheimer's disease: enlightenment to neurodegenerative diseases
by: Ying ZHANG
Published: (2014-04-01)